313TE targets IL-13Rα2-positive tumors in preclinical testing
Click to view quick news summary (Spoiler)
Preclinical studies indicate that the novel T-cell engager 313TE effectively targets and destroys IL-13Rα2-positive tumor cells in vitro and in mouse models.
A novel T-cell engager designated 313TE produced anti-tumor activity against IL-13Rα2-positive tumor cells in laboratory experiments and mouse xenografts, according to a research article published in Cancer Immunology, Immunotherapy. The construct was designed around an IL-13E13Y scaffold to bridge cells expressing IL-13Rα2 and T cells through CD3, enabling the two cell types to interact directly.
IL-13Rα2 was reported to be overexpressed in a variety of solid tumors and to have restricted expression in normal tissues. The authors identified this distribution as a reason to investigate the receptor as a target for cancer therapy, while noting that progress in developing IL-13Rα2-directed treatments has been limited. Their study focused on 313TE, a bispecific construct intended to connect the target on tumor cells with CD3 on T cells.
In vitro, 313TE bound strongly to IL-13Rα2-positive cells and T cells. Once the construct had linked these cell types, it promoted T-cell-mediated cytotoxicity against the targeted tumor cells. The killing was IL-13Rα2-dependent, rather than occurring without regard to receptor expression. The engager also elicited immune-stimulatory cytokines, indicating that its activity in the cell assays extended beyond the direct measurement of tumor-cell destruction.
The researchers then tested 313TE in a xenograft tumor model. Treatment significantly delayed tumor growth and reduced tumor weight compared with the study’s control condition. The efficacy was described as strictly dependent on IL-13Rα2 expression, linking the observed anti-tumor effect to the presence of the engager’s intended target. These findings show that 313TE could recruit T cells to IL-13Rα2-positive tumor cells under experimental conditions and suppress tumor growth in the mouse model.
The evidence is preclinical: it comes from cell-based assays and a mouse xenograft model, not from a clinical study in people with cancer. The results therefore support 313TE as an experimental targeted immunotherapy and do not establish clinical benefit in patients. The article presents the construct as a promising strategy for further investigation of IL-13Rα2-positive solid tumors, while the reported work remains limited to laboratory and animal models.
